Giovanni Tripepi

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/11749360/publications.pdf

Version: 2024-02-01

191 papers	14,519 citations	19657 61 h-index	20358 116 g-index
191 all docs	191 docs citations	191 times ranked	11521 citing authors

#	Article	IF	Citations
1	Translational research in nephrology: prognosis. CKJ: Clinical Kidney Journal, 2022, 15, 205-212.	2.9	0
2	The Role of Vitamin K in CKD-MBD. Current Osteoporosis Reports, 2022, 20, 65.	3.6	4
3	Early morning hemodynamic changes and left ventricular hypertrophy and mortality in hemodialysis patients. Journal of Nephrology, 2022, , .	2.0	1
4	Prognostic Factors of Fatal and Nonfatal Cardiovascular Events in Patients With Type 2 Diabetes: The Role of Renal Function Biomarkers. Clinical Diabetes, 2021, 39, 188-196.	2.2	2
5	Mutual effect modification between adiponectin and HDL as risk factors of cardiovascular events in Type 2 diabetes individuals: a cohort study. International Urology and Nephrology, 2021, 53, 2583-2591.	1.4	2
6	Clinical Epidemiology of Systolic and Diastolic Orthostatic Hypotension in Patients on Peritoneal Dialysis. Journal of Clinical Medicine, 2021, 10, 3075.	2.4	1
7	A randomized multicenter trial on a lung ultrasoundâ€“guided treatment strategy in patients on chronic hemodialysis with high cardiovascular risk. Kidney International, 2021, 100, 1325-1333.	5.2	45
8	Methods to Analyse Time-to-Event Data: The Kaplan-Meier Survival Curve. Oxidative Medicine and Cellular Longevity, 2021, 2021, 1-7.	4.0	18
9	Can the assessment of ultrasound lung water in haemodialysis patients be simplified?. Nephrology Dialysis Transplantation, 2021, 36, 2321-2326.	0.7	15
10	Overweight-obesity is associated with decreased vitamin K2 levels in hemodialysis patients. Clinical Chemistry and Laboratory Medicine, 2021, 59, 581-589.	2.3	5
11	The Vessels-Bone Axis: Iliac Artery Calcifications, Vertebral Fractures and Vitamin K from VIKI Study. Nutrients, 2021, 13, 3567.	4.1	6
12	Methods to Analyze Time-to-Event Data: The Cox Regression Analysis. Oxidative Medicine and Cellular Longevity, 2021, 2021, 1-6.	4.0	24
13	Lung ultrasound to detect and monitor pulmonary congestion in patients with acute kidney injury in nephrology wards: a pilot study. Journal of Nephrology, 2020, 33, 335-341.	2.0	7
14	Vitamin K2 is a key regulator of clinically relevant molecular processes. , 2020, , 153-172.		0
15	Inflammation is an amplifier of lung congestion by high lv filling pressure in hemodialysis patients: a longitudinal study. Journal of Nephrology, 2020, 33, 583-590.	2.0	4
16	FGF23 and the PTH response to paricalcitol in chronic kidney disease. European Journal of Clinical Investigation, 2020, 50, e13196.	3.4	8
17	Vitamin K and Osteoporosis. Nutrients, 2020, 12, 3625.	4.1	62
18	Vitamin K and Kidney Transplantation. Nutrients, 2020, 12, 2717.	4.1	6

#	Article	IF	Citations
19	Treatment-resistant hypertension in the hemodialysis population: a 44-h ambulatory blood pressure monitoring-based study. Journal of Hypertension, 2020, 38, 1849-1856.	0.5	15
20	Long-Term Changes in Sleep Disordered Breathing in Renal Transplant Patients: Relevance of the BMI. Journal of Clinical Medicine, 2020, 9, 1739.	2.4	5
21	Intention to treat and per protocol analysis in clinical trials. Nephrology, 2020, 25, 513-517.	1.6	101
22	Physical activity in chronic kidney disease and the EXerCise Introduction To Enhance trial. Nephrology Dialysis Transplantation, 2020, 35, ii18-ii22.	0.7	49
23	Sevelamer Use, Vitamin K Levels, Vascular Calcifications, and Vertebral Fractures in Hemodialysis Patients: Results from the VIKI Study. Journal of Bone and Mineral Research, 2020, 36, 500-509.	2.8	15
24	Oral Calcitriol Use, Vertebral Fractures, and Vitamin K in Hemodialysis Patients: A Cross-Sectional Study. Journal of Bone and Mineral Research, 2020, 36, 2361-2370.	2.8	2
25	Physical functioning and mortality in very old patients on dialysis. Archives of Gerontology and Geriatrics, 2019, 85, 103918.	3.0	2
26	Increased Risk of Bone Fractures in Hemodialysis Patients Treated with Proton Pump Inhibitors in Real World: Results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Journal of Bone and Mineral Research, 2019, 34, 2238-2245.	2.8	11
27	Serum Erythroferrone Levels Associate with Mortality and Cardiovascular Events in Hemodialysis and in CKD Patients: A Two Cohorts Study. Journal of Clinical Medicine, 2019, 8, 523.	2.4	14
28	Osteocalcin (bone GLA protein) levels, vascular calcifications, vertebral fractures and mortality in hemodialysis patients with diabetes mellitus. Journal of Nephrology, 2019, 32, 635-643.	2.0	16
29	Neuropeptide Y predicts cardiovascular events in chronic kidney disease patients. Journal of Hypertension, 2019, 37, 1359-1365.	0.5	10
30	Blood Pressure Variability, Mortality, and Cardiovascular Outcomes in CKD Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2019, 14, 233-240.	4.5	39
31	Vitamin D receptor activation raises soluble thrombomodulin levels in chronic kidney disease patients: a double blind, randomized trial. Nephrology Dialysis Transplantation, 2019, 34, 819-824.	0.7	6
32	Neuropeptide Y and chronic kidney disease progression: a cohort study. Nephrology Dialysis Transplantation, 2018, 33, 1805-1812.	0.7	18
33	Circulating adiponectin modifies the FGF23 response to vitamin D receptor activation: a post hoc analysis of a double-blind, randomized clinical trial. Nephrology Dialysis Transplantation, 2018, 33, 1764-1769.	0.7	8
34	The sirtuin1 gene associates with left ventricular myocardial hypertrophy and remodeling in two chronic kidney disease cohorts. Journal of Hypertension, 2018, 36, 1705-1711.	0.5	6
35	Office, standardized and 24-h ambulatory blood pressure and renal function loss in renal transplant patients. Journal of Hypertension, 2018, 36, 119-125.	0.5	23
36	The dominant prognostic value of physical functioning among quality of life domains in end-stage kidney disease. Nephrology Dialysis Transplantation, 2018, 35, 170-175.	0.7	4

#	Article	IF	Citations
37	Effect of a home based, low intensity, physical exercise program in older adults dialysis patients: a secondary analysis of the EXCITE trial. BMC Geriatrics, 2018, 18, 248.	2.7	59
38	Low vitamin K1 intake in haemodialysis patients. Clinical Nutrition, 2017, 36, 601-607.	5.0	40
39	Do we still need cross-sectional studies in Nephrology? Yes we do!. Nephrology Dialysis Transplantation, 2017, 32, gfw439.	0.7	5
40	Chronic Fluid Overload and Mortality in ESRD. Journal of the American Society of Nephrology: JASN, 2017, 28, 2491-2497.	6.1	286
41	Exercise in Patients on Dialysis: A Multicenter, Randomized Clinical Trial. Journal of the American Society of Nephrology: JASN, 2017, 28, 1259-1268.	6.1	272
42	Reappraisal in two European cohorts ofÂtheÂprognostic power of left ventricular massÂindexÂin chronic kidney failure. Kidney International, 2017, 91, 704-710.	5.2	13
43	Long-Term Progression of Coronary Artery Calcification Is Independent of Classical Risk Factors, C-Reactive Protein, and Parathyroid Hormone in Renal Transplant Patients. CardioRenal Medicine, 2017, 7, 284-294.	1.9	9
44	Effect of Vitamin D Receptor Activation on the AGE/RAGE System and Myeloperoxidase in Chronic Kidney Disease Patients. Oxidative Medicine and Cellular Longevity, 2017, 2017, 1-7.	4.0	7
45	Vitamin D and methylarginines in chronic kidney disease (CKD). PLoS ONE, 2017, 12, e0185449.	2.5	3
46	Nocturnal Hypertension and Altered Nightâ€“Day BP Profile and Atherosclerosis in Renal Transplant Patients. Transplantation, 2016, 100, 2211-2218.	1.0	27
47	Intact FGF23 and Î±â€klotho during acute inflammation/sepsis in CKD patients. European Journal of Clinical Investigation, 2016, 46, 234-241.	3.4	28
48	Efficacy of a remote web-based lung ultrasound training for nephrologists and cardiologists: a LUST trial sub-project. Nephrology Dialysis Transplantation, 2016, 31, 1982-1988.	0.7	60
49	Body mass index trend in haemodialysis patients: the shift of nutritional disorders in two Italian regions. Nephrology Dialysis Transplantation, 2016, 31, 1699-1705.	0.7	29
50	The Agreement between Auscultation and Lung Ultrasound in Hemodialysis Patients: The LUST Study. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 2005-2011.	4.5	124
51	Renal Biopsy in 2015 - From Epidemiology to Evidence-Based Indications. American Journal of Nephrology, 2016, 43, 1-19.	3.1	106
52	Physical exercise in haemodialysis patients: time to start. Nephrology Dialysis Transplantation, 2016, 31, 1196-1198.	0.7	6
53	Calcimimetic and vitamin D analog use in hemodialyzed patients is associated with increased levels of vitamin K dependent proteins. Endocrine, 2016, 51, 333-341.	2.3	21
54	Subclinical pulmonary congestion is prevalent in nephrotic syndrome. Kidney International, 2016, 89, 421-428.	5.2	21

#	Article	IF	Citations
55	Aldosterone, mortality, cardiovascular events and reverse epidemiology in end stage renal disease. European Journal of Clinical Investigation, 2015, 45, 1077-1086.	3.4	8
56	Moderator's view: Ambulatory blood pressure monitoring and home blood pressure for the prognosis, diagnosis and treatment of hypertension in dialysis patients. Nephrology Dialysis Transplantation, 2015, 30, 1443-1448.	0.7	30
57	Serum Alkaline Phosphatase Negatively Affects Endothelium-Dependent Vasodilation in NaÃ¯ve Hypertensive Patients. Hypertension, 2015, 66, 874-880.	2.7	34
58	The Role of Deconditioning in the End-Stage Renal Disease Myopathy: Physical Exercise Improves Altered Resting Muscle Oxygen Consumption. American Journal of Nephrology, 2015, 41, 329-336.	3.1	41
59	Should we extend the application of more frequent dialysis schedules? A 'yes' and a hopeful 'no'. Nephrology Dialysis Transplantation, 2015, 30, 29-32.	0.7	2
60	Association of IL-6 and a Functional Polymorphism in the IL-6 Gene with Cardiovascular Events in Patients with CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 232-240.	4.5	64
61	Norepinephrine, left ventricular disorders and volume excess in ESRD. Journal of Nephrology, 2015, 28, 729-737.	2.0	4
62	Asymmetric and Symmetric Dimethylarginine and Sympathetic Nerve Traffic after Renal Denervation in Patients with Resistant Hypertension. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 1560-1567.	4.5	11
63	Analysis of risk factors associated with renal function trajectory over time: a comparison of different statistical approaches. Nephrology Dialysis Transplantation, 2015, 30, 1237-1243.	0.7	81
64	Insulin-resistance HCV infection-related affects vascular stiffness in normotensives. Atherosclerosis, 2015, 238, 108-112.	0.8	17
65	Competitive Interaction Between Fibroblast Growth Factor 23 And Asymmetric Dimethylarginine in Patients With CKD. Journal of the American Society of Nephrology: JASN, 2015, 26, 935-944.	6.1	21
66	Prevalence of Vertebral Fractures, Vascular Calcifications, and Mortality in Warfarin Treated Hemodialysis Patients. Current Vascular Pharmacology, 2015, 13, 248-258.	1.7	62
67	Paricalcitol and Endothelial Function in Chronic Kidney Disease Trial. Hypertension, 2014, 64, 1005-1011.	2.7	106
68	Chronic Kidney Disease (CKD) as a Systemic Disease: Whole Body Autoregulation and Inter-Organ Cross-Talk. Kidney and Blood Pressure Research, 2014, 39, 134-141.	2.0	6
69	Physical Performance and Clinical Outcomes in Dialysis Patients: A Secondary Analysis of the Excite Trial. Kidney and Blood Pressure Research, 2014, 39, 205-211.	2.0	72
70	Fluid overload and post-dialysis hypertension. Nature Reviews Nephrology, 2014, 10, 623-624.	9.6	1
71	High Prevalence of Vertebral Fractures Assessed by Quantitative Morphometry in Hemodialysis Patients, Strongly Associated with Vascular Calcifications. Calcified Tissue International, 2013, 93, 39-47.	3.1	42
72	Asymmetric dimethylarginine predicts survival in the elderly. Age, 2013, 35, 2465-2475.	3.0	31

#	Article	IF	Citations
73	Prevalence of renal artery stenosis in patients undergoing cardiac catheterization. Internal and Emergency Medicine, 2013, 8, 401-408.	2.0	11
74	Value of Troponin T as a Screening Test for Left Ventricular Hypertrophy in CKD. American Journal of Kidney Diseases, 2013, 61, 689-691.	1.9	2
75	Obesity and CKD progression: hard facts on fat CKD patients. Nephrology Dialysis Transplantation, 2013, 28, iv105-iv108.	0.7	36
76	Salt and the heart in chronic kidney disease: an atrial connection. Nephrology Dialysis Transplantation, 2013, 28, 2210-2211.	0.7	5
77	Resistin and all-cause and cardiovascular mortality: effect modification by adiponectin in end-stage kidney disease patients. Nephrology Dialysis Transplantation, 2013, 28, iv181-iv187.	0.7	30
78	Phosphate attenuates the anti-proteinuric effect of very low-protein diet in CKD patients. Nephrology Dialysis Transplantation, 2013, 28, 632-640.	0.7	73
79	Pulmonary Congestion Predicts Cardiac Events and Mortality in ESRD. Journal of the American Society of Nephrology: JASN, 2013, 24, 639-646.	6.1	221
80	Asymptomatic Pulmonary Congestion and Physical Functioning in Hemodialysis Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2013, 8, 1343-1348.	4.5	50
81	Lung Congestion as a Risk Factor in End-Stage Renal Disease. Blood Purification, 2013, 36, 184-191.	1.8	32
82	Long-term visit-to-visit office blood pressure variability increases the risk of adverse cardiovascular outcomes in patients with chronic kidney disease. Kidney International, 2013, 84, 381-389.	5.2	65
83	Risk prediction models. Nephrology Dialysis Transplantation, 2013, 28, 1975-1980.	0.7	36
84	The fat-mass and obesity-associated gene (FTO) predicts mortality in chronic kidney disease of various severity. Nephrology Dialysis Transplantation, 2012, 27, iv58-iv62.	0.7	15
85	Assessment of obesity in chronic kidney disease. Current Opinion in Nephrology and Hypertension, 2012, 21, 641-646.	2.0	56
86	Insulin resistance and left ventricular hypertrophy in end-stage renal disease: association between the ENPP1 gene and left ventricular concentric remodelling. Nephrology Dialysis Transplantation, 2012, 27, 661-666.	0.7	9
87	Tissue inhibitor of metalloproteinases (TIMP-1), genetic markers of insulin resistance and cardiomyopathy in patients with kidney failure. Nephrology Dialysis Transplantation, 2012, 27, 2440-2445.	0.7	3
88	eNOS and Caveolin-1 Gene Polymorphisms Interaction and Intima Media Thickness: A Proof of Concept Study in ESRD Patients. American Journal of Hypertension, 2012, 25, 103-108.	2.0	15
89	Vitamin K, vertebral fractures, vascular calcifications, and mortality: Vitamin K Italian (VIKI) dialysis study. Journal of Bone and Mineral Research, 2012, 27, 2271-2278.	2.8	122
90	An overview on standard statistical methods for assessing exposure-outcome link in survival analysis (Part II): the Kaplan-Meier analysis and the Cox regression method. Aging Clinical and Experimental Research, 2012, 24, 203-206.	2.9	29

#	Article	IF	Citations
91	Prognostic models in the clinical arena. Aging Clinical and Experimental Research, 2012, 24, 300-304.	2.9	4
92	Pro-inflammatory cytokines and bone fractures in CKD patients. An exploratory single centre study. BMC Nephrology, 2012, 13, 134.	1.8	23
93	Effect of Renal Artery Stenting on Left Ventricular Mass: A Randomized Clinical Trial. American Journal of Kidney Diseases, 2012, 60, 39-46.	1.9	45
94	Aging and Left Ventricular Mass and Function in People with Endâ€Stage Renal Disease. Journal of the American Geriatrics Society, 2011, 59, 1636-1641.	2.6	7
95	Sympathetic Nerve Traffic and Asymmetric Dimethylarginine in Chronic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 2620-2627.	4.5	46
96	Inflammation and Asymmetric Dimethylarginine for Predicting Death and Cardiovascular Events in ESRD Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 1714-1721.	4.5	98
97	Phosphate May Promote CKD Progression and Attenuate Renoprotective Effect of ACE Inhibition. Journal of the American Society of Nephrology: JASN, 2011, 22, 1923-1930.	6.1	190
98	Comment accompanying: obstructive sleep apnoea: a stand-alone risk factor for chronic kidney disease by Chou Yu-Ting. Nephrology Dialysis Transplantation, 2011, 26, 2072-2074.	0.7	7
99	ACE Inhibition Is Renoprotective among Obese Patients with Proteinuria. Journal of the American Society of Nephrology: JASN, 2011, 22, 1122-1128.	6.1	119
100	Abdominal obesity modifies the risk of hypertriglyceridemia for all-cause and cardiovascular mortality in hemodialysis patients. Kidney International, 2011, 79, 765-772.	5.2	39
101	Neuropeptide Y receptor Y2 gene polymorphism interacts with plasma neuropeptide Y levels in predicting left ventricular hypertrophy in dialysis patients. Journal of Hypertension, 2010, 28, 1745-1751.	0.5	9
102	Vitamin D receptor (VDR) gene polymorphism is associated with left ventricular (LV) mass and predicts left ventricular hypertrophy (LVH) progression in end-stage renal disease (ESRD) patients. Journal of Bone and Mineral Research, 2010, 25, 313-319.	2.8	59
103	Soluble E-Selectin Is an Inverse and Independent Predictor of Left Ventricular Wall Thickness in End-Stage Renal Disease Patients. Nephron Clinical Practice, 2010, 114, c74-c80.	2.3	5
104	Measures of Effect in Epidemiological Research. Nephron Clinical Practice, 2010, 115, c91-c93.	2.3	7
105	Sample size calculations: basic principles and common pitfalls. Nephrology Dialysis Transplantation, 2010, 25, 1388-1393.	0.7	302
106	Circulating soluble receptor of advanced glycation end product inversely correlates with atherosclerosis in patients with chronic kidney disease. Kidney International, 2010, 77, 225-231.	5.2	60
107	Statistical methods for the assessment of prognostic biomarkers (Part I): Discrimination. Nephrology Dialysis Transplantation, 2010, 25, 1399-1401.	0.7	68
108	Statistical methods for the assessment of prognostic biomarkers(part II): calibration and re-classification. Nephrology Dialysis Transplantation, 2010, 25, 1402-1405.	0.7	41

#	Article	IF	Citations
109	Detection of Pulmonary Congestion by Chest Ultrasound in Dialysis Patients. JACC: Cardiovascular Imaging, 2010, 3, 586-594.	5.3	232
110	Traditional and nontraditional risk factors as predictors of cerebrovascular events in patients with end stage renal disease. Journal of Hypertension, 2010, 28, 2468-2474.	0.5	14
111	Biomarkers of Left Atrial Volume. Hypertension, 2009, 54, 818-824.	2.7	49
112	Vitamin D levels and patient outcome in chronic kidney disease. Kidney International, 2009, 75, 88-95.	5.2	384
113	Abdominal Obesity and All-Cause and Cardiovascular Mortality in End-Stage Renal Disease. Journal of the American College of Cardiology, 2009, 53, 1265-1272.	2.8	279
114	Methylarginines and mortality in patients with end stage renal disease: A prospective cohort study. Atherosclerosis, 2009, 207, 541-545.	0.8	60
115	Diagnostic methods 2: receiver operating characteristic (ROC) curves. Kidney International, 2009, 76, 252-256.	5.2	60
116	Kidney Function and Risk Factors for Left Ventricular Hypertrophy in Untreated Uncomplicated Essential Hypertension. American Journal of Kidney Diseases, 2008, 52, 74-84.	1.9	27
117	Sleep quality in patients with chronic renal failure: A 3-year longitudinal study. Sleep Medicine, 2008, 9, 240-246.	1.6	47
118	Urotensin II and Cardiomyopathy in End-Stage Renal Disease. Hypertension, 2008, 51, 326-333.	2.7	19
119	Rate of Atherosclerotic Plaque Formation Predicts Cardiovascular Events in ESRD. Journal of the American Society of Nephrology: JASN, 2008, 19, 757-763.	6.1	41
120	Testing for causality and prognosis: etiological and prognostic models. Kidney International, 2008, 74, 1512-1515.	5.2	45
121	Vascular endothelial growth factor, left ventricular dysfunction and mortality in hemodialysis patients. Journal of Hypertension, 2008, 26, 1875-1882.	0.5	24
122	Asymmetric dimethyl-arginine (ADMA) response to inflammation in acute infections. Nephrology Dialysis Transplantation, 2007, 22, 801-806.	0.7	592
123	Searching for biomarker patterns characterizing carotid atherosclerotic burden in patients with reduced renal function. Nephrology Dialysis Transplantation, 2007, 22, 3521-3526.	0.7	32
124	Prognostic value of the New York Heart Association classification in end-stage renal disease. Nephrology Dialysis Transplantation, 2007, 22, 1377-1382.	0.7	34
125	Left Atrial Volume Monitoring and Cardiovascular Risk in Patients with End-Stage Renal Disease. Journal of the American Society of Nephrology: JASN, 2007, 18, 1316-1322.	6.1	78
126	An Additive Effect of Endothelial Nitric Oxide Synthase Gene Polymorphisms Contributes to the Severity of Atherosclerosis in Patients on Dialysis. American Journal of Hypertension, 2007, 20, 758-763.	2.0	9

#	Article	IF	Citations
127	Guest Editor: Rajiv Agarwal: Cardiovascular Risk Profile Assessment and Medication Control Should Come First. Seminars in Dialysis, 2007, 20, 405-408.	1.3	1
128	CARDIOVASCULAR AND SURVIVAL PARADOXES IN DIALYSIS PATIENTS: It Is Important to Lower Homocysteine in Dialysis Patients. Seminars in Dialysis, 2007, 20, 530-533.	1.3	8
129	Urotensin II and Biomarkers of Endothelial Activation and Atherosclerosis in End-Stage Renal Disease. American Journal of Hypertension, 2006, 19, 505-510.	2.0	21
130	Low triiodothyronine and cardiomyopathy in patients with end-stage renal disease. Journal of Hypertension, 2006, 24, 2039-2046.	0.5	55
131	Left atrial volume in end-stage renal disease: a prospective cohort study. Journal of Hypertension, 2006, 24, 1173-1180.	0.5	90
132	Asymmetric dimethylarginine (ADMA) as a cardiovascular risk factor in end-stage renal disease (ESRD). European Journal of Clinical Pharmacology, 2006, 62, 131-135.	1.9	8
133	Mendelian Randomization: A New Approach to Studying Epidemiology in ESRD. American Journal of Kidney Diseases, 2006, 47, 332-341.	1.9	43
134	The E-selectin gene polymorphism and carotid atherosclerosis in end-stage renal disease. Nephrology Dialysis Transplantation, 2006, 21, 1921-1926.	0.7	18
135	Subclinical hypothyroidism is linked to micro-inflammation and predicts death in continuous ambulatory peritoneal dialysis. Nephrology Dialysis Transplantation, 2006, 22, 538-544.	0.7	94
136	Is oxidative stress implicated in high bone turnover in end-stage renal disease (ESRD)?. Nephrology Dialysis Transplantation, 2006, 21, 1735-1736.	0.7	0
137	Dissecting Inflammation in ESRD: Do Cytokines and C-Reactive Protein Have a Complementary Prognostic Value for Mortality in Dialysis Patients?. Journal of the American Society of Nephrology: JASN, 2006, 17, S169-S173.	6.1	101
138	Inflammation as a Mediator of the Link between Mild to Moderate Renal Insufficiency and Endothelial Dysfunction in Essential Hypertension. Journal of the American Society of Nephrology: JASN, 2006, 17, S64-S68.	6.1	39
139	Left Ventricular Systolic Function Monitoring in Asymptomatic Dialysis Patients: A Prospective Cohort Study. Journal of the American Society of Nephrology: JASN, 2006, 17, 1460-1465.	6.1	48
140	The GLU298ASP variant of nitric oxide synthase interacts with asymmetric dimethyl arginine in determining cardiovascular mortality in patients with end-stage renal disease. Journal of Hypertension, 2005, 23, 1825-1830.	0.5	27
141	Prognostic value of combined use of biomarkers of inflammation, endothelial dysfunction, and myocardiopathy in patients with ESRD. Kidney International, 2005, 67, 2330-2337.	5.2	116
142	Prognostic value of 24-hour ambulatory blood pressure monitoring and of night/day ratio in nondiabetic, cardiovascular events-free hemodialysis patients. Kidney International, 2005, 68, 1294-1302.	5.2	114
143	Hyperhomocysteinemia and arteriovenous fistula thrombosis in hemodialysis patients. American Journal of Kidney Diseases, 2005, 45, 702-707.	1.9	42
144	Clinical Epidemiology of Major Nontraditional Risk Factors in Peritoneal Dialysis Patients. Peritoneal Dialysis International, 2005, 25, 84-87.	2.3	29

#	Article	IF	Citations
145	Inflammation Markers, Adhesion Molecules, and All-Cause and Cardiovascular Mortality in Patients with ESRD. Journal of the American Society of Nephrology: JASN, 2005, 16, S83-S88.	6.1	217
146	Asymmetrical Dimethylarginine Predicts Progression to Dialysis and Death in Patients with Chronic Kidney Disease. Journal of the American Society of Nephrology: JASN, 2005, 16, 2449-2455.	6.1	352
147	Low Triiodothyronine. Journal of the American Society of Nephrology: JASN, 2005, 16, 2789-2795.	6.1	132
148	Predictors of Cardiovascular Death in ESRD. Seminars in Nephrology, 2005, 25, 358-362.	1.6	76
149	Adipose tissue cytokines, insulin sensitivity, inflammation, and cardiovascular outcomes in end-stage renal disease patients. , 2005, 15, 125-130.		45
150	Atherosclerosis and the Glu298Asp Polymorphism of the eNOS Gene in White Patients With End-Stage Renal Disease. American Journal of Hypertension, 2005, 18, 1549-1555.	2.0	14
151	Prognostic Value of Echocardiographic Indicators of Left Ventricular Systolic Function in Asymptomatic Dialysis Patients. Journal of the American Society of Nephrology: JASN, 2004, 15, 1029-1037.	6.1	180
152	Analysis of the Relationship between Norepinephrine and Asymmetric Dimethyl Arginine Levels among Patients with End-Stage Renal Disease. Journal of the American Society of Nephrology: JASN, 2004, 15, 435-441.	6.1	93
153	Novel Cardiovascular Risk Factors in End-Stage Renal Disease. Journal of the American Society of Nephrology: JASN, 2004, 15, S77-S80.	6.1	120
154	Inflammatory proteins as predictors of cardiovascular disease in patients with end-stage renal disease. Nephrology Dialysis Transplantation, 2004, 19, v67-v72.	0.7	62
155	Endothelial Dysfunction and Mild Renal Insufficiency in Essential Hypertension. Circulation, 2004, 110, 821-825.	1.6	94
156	Left ventricular mass monitoring in the follow-up of dialysis patients: Prognostic value of left ventricular hypertrophy progression. Kidney International, 2004, 65, 1492-1498.	5.2	299
157	HYPERTENSION IN HEMODIALYSIS PATIENTS: Cardiac Consequences of Hypertension in Hemodialysis Patients. Seminars in Dialysis, 2004, 17, 299-303.	1.3	38
158	Heart valve calcifications, survival, and cardiovascular risk in hemodialysis patients. American Journal of Kidney Diseases, 2004, 43, 479-484.	1.9	47
159	Chlamydia pneumoniae, overall and cardiovascular mortality in end-stage renal disease (ESRD). Kidney International, 2003, 64, 579-584.	5.2	22
160	Adiponectin is markedly increased in patients with nephrotic syndrome and is related to metabolic risk factors. Kidney International, 2003, 63, S98-S102.	5.2	110
161	Adipose tissue as a source of inflammatory cytokines in health and disease: Focus on end-stage renal disease. Kidney International, 2003, 63, S65-S68.	5.2	72
162	Traditional and emerging cardiovascular risk factors in end-stage renal disease. Kidney International, 2003, 63, S105-S110.	5.2	168

#	Article	IF	Citations
163	Hepatocyte Growth Factor and Left Ventricular Geometry in End-Stage Renal Disease. Hypertension, 2003, 41, 88-92.	2.7	27
164	Prospective Study of Neuropeptide Y as an Adverse Cardiovascular Risk Factor in End-Stage Renal Disease. Journal of the American Society of Nephrology: JASN, 2003, 14, 2611-2617.	6.1	48
165	Neuropeptide Y, left ventricular mass and function in patients with end stage renal disease. Journal of Hypertension, 2003, 21, 1355-1362.	0.5	23
166	Inflammation and Atherosclerosis in End-Stage Renal Disease. Blood Purification, 2003, 21, 29-36.	1.8	76
167	Plasma Norepinephrine Predicts Survival and Incident Cardiovascular Events in Patients With End-Stage Renal Disease. Circulation, 2002, 105, 1354-1359.	1.6	485
168	Norepinephrine and Concentric Hypertrophy in Patients With End-Stage Renal Disease. Hypertension, 2002, 40, 41-46.	2.7	123
169	Nocturnal Hypoxemia: A Neglected Cardiovascular Risk Factor in End-Stage Renal Disease?. Blood Purification, 2002, 20, 120-123.	1.8	20
170	Troponin is related to left ventricular mass and predicts all-cause and cardiovascular mortality in hemodialysis patients. American Journal of Kidney Diseases, 2002, 40, 68-75.	1.9	144
171	Hypertension as a cardiovascular risk factor in end-stage renal failure. Current Hypertension Reports, 2002, 4, 381-386.	3.5	18
172	Hyperhomocysteinemia predicts cardiovascular outcomes in hemodialysis patients. Kidney International, 2002, 61, 609-614.	5.2	247
173	Left ventricular hypertrophy, cardiac remodeling and asymmetric dimethylarginine (ADMA) in hemodialysis patients. Kidney International, 2002, 62, 339-345.	5.2	194
174	Inflammation and outcome in end-stage renal failure: Does female gender constitute a survival advantage?. Kidney International, 2002, 62, 1791-1798.	5.2	175
175	Diagnostic value of troponin T for alterations in left ventricular mass and function in dialysis patients. Kidney International, 2002, 62, 1884-1890.	5.2	66
176	Adiponectin, Metabolic Risk Factors, and Cardiovascular Events among Patients with End-Stage Renal Disease. Journal of the American Society of Nephrology: JASN, 2002, 13, 134-141.	6.1	560
177	Asymmetric Dimethylarginine, C-Reactive Protein, and Carotid Intima-Media Thickness in End-Stage Renal Disease. Journal of the American Society of Nephrology: JASN, 2002, 13, 490-496.	6.1	235
178	Nocturnal Hypoxemia Predicts Incident Cardiovascular Complications in Dialysis Patients. Journal of the American Society of Nephrology: JASN, 2002, 13, 729-733.	6.1	122
179	Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet, The, 2001, 358, 2113-2117.	13.7	993
180	Left ventricular hypertrophy and nocturnal hypoxemia in hemodialysis patients. Journal of Hypertension, 2001, 19, 287-293.	0.5	52

#	Article	IF	Citations
181	Longâ€term CAPD patients are volume expanded and display more severe left ventricular hypertrophy than haemodialysis patients. Nephrology Dialysis Transplantation, 2001, 16, 1459-1464.	0.7	181
182	Diagnostic potential of cardiac natriuretic peptides in dialysis patients. Kidney International, 2001, 59, 1559-1566.	5.2	145
183	Autonomic neuropathy is linked to nocturnal hypoxaemia and to concentric hypertrophy and remodelling in dialysis patients. Nephrology Dialysis Transplantation, 2001, 16, 70-77.	0.7	121
184	Prognostic Value of Ultrasonographic Measurement of Carotid Intima Media Thickness in Dialysis Patients. Journal of the American Society of Nephrology: JASN, 2001, 12, 2458-2464.	6.1	166
185	Prognostic Impact of the Indexation of Left Ventricular Mass in Patients Undergoing Dialysis. Journal of the American Society of Nephrology: JASN, 2001, 12, 2768-2774.	6.1	246
186	Sleep Apnea in Renal Patients. Journal of the American Society of Nephrology: JASN, 2001, 12, 2854-2859.	6.1	72
187	Cardiac Natriuretic Peptides Are Related to Left Ventricular Mass and Function and Predict Mortality in Dialysis Patients. Journal of the American Society of Nephrology: JASN, 2001, 12, 1508-1515.	6.1	270
188	Inflammation is associated with carotid atherosclerosis in dialysis patients. Journal of Hypertension, 2000, 18, 1207-1213.	0.5	179
189	Hepatocyte growth factor predicts survival and relates to inflammation and intima media thickness in end-stage renal disease. American Journal of Kidney Diseases, 2000, 36, 945-952.	1.9	56
190	Prediction of left ventricular geometry by clinic, pre-dialysis and 24-h ambulatory BP monitoring in hemodialysis patients. Journal of Hypertension, 1999, 17, 1751-1758.	0.5	92
191	Nocturnal hypoxemia, night-day arterial pressure changes and left ventricular geometry in dialysis patients. Kidney International, 1998, 53, 1078-1084.	5.2	120